Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 875 results for "gsk"

Societe Generale Analyst Reaffirmed GBX 1300.00 Price Target on Glaxosmithkline (LON:GSK) stock, While Reiterating Sell Rating

Independent Research GmbH Analysts Give GlaxoSmithKline plc (G...

Independent Research GmbH set a GBX 1,550 ($22.72) target price on GlaxoSmithKline plc (LON:GSK) in a report issued on Thursday morning, Market reports. The firm currently has a a neutral rating on the stock. In other GlaxoSmithKline plc ... Mideast Time, 18 hours ago
Contract Pharma

Codexis Completes CodeEvolver® Technology Transfer To GSK; Earns $7.5 Million Milestone Payment

(GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the completion of the third and final Wave in the transfer of its proprietary CodeEvolver ® protein engineering platform technology to GlaxoSmithKline ...
 TheStreet.com1 day ago Codexis Completes Tech Transfer to GSK  Contract Pharma1 day ago CODEXIS : Completes CodeEvolver Technology Transfer to GSK; Earns $7.5 Million Milestone Payment  4 Traders10 hours ago Codexis completes CodeEvolver technology transfer to GSK  Manufacturing Chemist16 hours ago

GSK eyes a big bite of teeth whitening segment

The toothpaste will be exclusively available on Snapdeal this month
 Business Line7 hours ago

National survey of uncontrolled asthma patients finds majority mistakenly believe their asthma is under control

RESEARCH TRIANGLE PARK, N.C., May 3, 2016 /PRNewswire/ -- GSK today released data from a new national survey of more than 1,000 uncontrolled asthma patients showing that 67% of adults with uncontrolled asthma in the US are living with the ...
 Bloomberg13 hours ago GlaxoSmithKline Release: National Survey Of Uncontrolled Asthma Patients Finds Majority Mistakenly Believe Their Asthma Is Under Control  BioSpace11 hours ago
Motley Fool

Does This Upstart Pose a Threat to GlaxoSmithKline?

SOURCE: GLAXOSMITHKLINE PLC. GlaxoSmithKline plc ( NYSE:GSK ) generates more than $1.2 billion per quarter selling vaccines that are used to treat infectious disease, and one of GlaxoSmithKline's top-selling vaccines is Engerix-B, a vaccine used ...
 Motley Fool13 hours ago Dynavax's Possible Hep B Win Could Prove a Threat to GlaxoSmithKline  BioSpace11 hours ago

The numbers don't lie, GlaxoSmithKline plc is set to beat AstraZeneca plc this year

GlaxoSmithKline (LSE: GSK) has made a great start to 2016. The company's first-quarter results released at the end of last week, showed that Glaxo is on course to increase earnings by 10% to 12% this year, which is slightly ahead of market ...
 Motley Fool UK16 hours ago
Charity Today News

EMA committee backs GSK, Save the Children's antiseptic chlorhexidine gel for newborn umbilical cord infections

An antiseptic chlorhexidine gel to prevent umbilical cord infections (omphalitis) in newborn infants in developing countries, advanced through GSK and Save the Children's groundbreaking partnership, has been granted a positive scientific opinion ...
 PharmaBiz19 hours ago Gel developed through partnership can help save newborn lives  Charity Today News16 hours ago

In-depth: MSF takes on Pfizer, GSK

Medicins Sans Frontieres (MSF) recently stepped up their campaign to make the pneumonia vaccine more available in developing countries. Appearing to stand in their way are the makers of the vaccine, GSK and Pfizer. In March, MSF formally ...
 Pharmafile14 hours ago Petition urges GSK and Pfizer to lower price of pneumonia vaccine  British Medical Journal4 days ago MSF delivers petition of over 400,000 people who demand Pfizer and GSK cut the price of pneumonia vaccine  Foreign days ago More than 400,000 Demand Pfizer and GSK Cut Price of Lifesaving Pneumonia Vaccine  MSF-USA6 days ago

GlaxoSmithKline CEO Sells 10,000 Shares/1,475P

Glaxosmithkline (LSE:GSK) Historical Stock Chart 1 Month : From Apr 2016 to May 2016 LONDON-- Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) Thursday said its Chief Executive Andrew Witty sold 10,000 shares at 1,475 pence a share. ...
 Investors Hub13 hours ago GlaxoSmithKline recovery on track claims chief  MENAFN5 days ago GLAXOSMITHKLINE : CEO Sells 10,000 Shares/1,475P  4 Traders5 days ago

GSK CEO: Big pharma should keep investing in R&D

GlaxoSmithKline CEO Andrew Witty attributes the company's success to sticking to the tried-and-true business model of investing in research and development and not transitioning to an acquisition model. Witty told CNBC's "Closing Bell" on Monday ...
 CNBC1 day ago GSK CEO: Drug pricing in the US needs to change, here's how  CNBC1 day ago BRIEF-GSK CEO expects successor to be named towards end of 2016  Reuters UK6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gsk
Get updated on latest news & your favorite topics right in your inbox!
More     Less